Wilbur H. (bill) Gantz
Aevi Genomic Medicine Inc
United States of America
Mr. Gantz is President of PathoCapital, an investor in healthcare companies. He previously was Executive Chairman of Naurex Inc., which was sold to Allergan in 2015. He also served as Executive Chairman and Chief Executive Officer of Ovation Pharmaceuticals, Inc., which was sold to Lundbeck, AG in 2009, and, as Chairman, Chief Executive Officer and President of PathoGenesis Corporation, a biopharmaceutical company that was sold to Chiron, Inc. in 2000. Prior to founding PathoGenesis, from 1987 to 1992 he served as President of Baxter International, Inc., a manufacturer and marketer of healthcare products. He joined Baxter in 1966 and held various management positions, including Vice President, Europe and President, International Division, prior to being named Executive Vice President and Chief Operating Officer in 1980. Mr. Gantz holds a BA degree from Princeton University, where he graduated cum laude, and an M.B.A. from Harvard Business School.
Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.